Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 20 studies | 30% ± 13% | |
peripheral blood | 16 studies | 36% ± 11% | |
brain | 15 studies | 33% ± 14% | |
intestine | 10 studies | 38% ± 21% | |
eye | 10 studies | 34% ± 16% | |
kidney | 9 studies | 32% ± 14% | |
liver | 7 studies | 37% ± 20% | |
lymph node | 6 studies | 37% ± 15% | |
heart | 6 studies | 28% ± 8% | |
pancreas | 5 studies | 35% ± 13% | |
bone marrow | 5 studies | 31% ± 13% | |
breast | 5 studies | 33% ± 9% | |
uterus | 4 studies | 45% ± 8% | |
prostate | 4 studies | 25% ± 4% | |
adipose | 4 studies | 33% ± 7% | |
placenta | 3 studies | 24% ± 10% | |
adrenal gland | 3 studies | 29% ± 9% | |
skin | 3 studies | 23% ± 2% | |
thymus | 3 studies | 57% ± 27% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 12330.24 | 459 / 459 | 100% | 119.46 | 1118 / 1118 |
esophagus | 100% | 8718.18 | 1445 / 1445 | 100% | 99.59 | 183 / 183 |
lung | 100% | 10172.26 | 578 / 578 | 100% | 97.75 | 1155 / 1155 |
ovary | 100% | 22926.74 | 180 / 180 | 100% | 118.29 | 430 / 430 |
stomach | 100% | 8817.23 | 359 / 359 | 100% | 102.37 | 286 / 286 |
uterus | 100% | 15740.66 | 170 / 170 | 100% | 108.86 | 459 / 459 |
thymus | 100% | 13502.44 | 653 / 653 | 100% | 123.59 | 604 / 605 |
intestine | 100% | 10980.91 | 966 / 966 | 100% | 108.27 | 526 / 527 |
bladder | 100% | 10512.05 | 21 / 21 | 100% | 98.79 | 503 / 504 |
prostate | 100% | 11466.44 | 245 / 245 | 100% | 93.82 | 501 / 502 |
pancreas | 100% | 7688.53 | 327 / 328 | 100% | 71.25 | 178 / 178 |
kidney | 100% | 8787.57 | 89 / 89 | 100% | 83.28 | 898 / 901 |
brain | 99% | 5585.05 | 2619 / 2642 | 100% | 109.89 | 705 / 705 |
skin | 100% | 9727.66 | 1809 / 1809 | 99% | 87.99 | 466 / 472 |
adrenal gland | 100% | 8863.89 | 258 / 258 | 99% | 63.05 | 227 / 230 |
liver | 99% | 3951.00 | 224 / 226 | 97% | 43.71 | 393 / 406 |
adipose | 100% | 11120.95 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 9833.46 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 122.30 | 29 / 29 |
muscle | 100% | 8446.52 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 13441.78 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 100.40 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 39.33 | 1 / 1 |
heart | 99% | 6488.43 | 849 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 95.21 | 78 / 80 |
peripheral blood | 91% | 7337.07 | 844 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0051260 | Biological process | protein homooligomerization |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0048026 | Biological process | positive regulation of mRNA splicing, via spliceosome |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0048025 | Biological process | negative regulation of mRNA splicing, via spliceosome |
GO_0006509 | Biological process | membrane protein ectodomain proteolysis |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005615 | Cellular component | extracellular space |
GO_0005681 | Cellular component | spliceosomal complex |
GO_0016020 | Cellular component | membrane |
GO_0000791 | Cellular component | euchromatin |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0044530 | Cellular component | supraspliceosomal complex |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0003729 | Molecular function | mRNA binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RBMX |
Protein name | RNA binding motif protein X-linked RNA-binding motif protein, X chromosome (Glycoprotein p43) (Heterogeneous nuclear ribonucleoprotein G) (hnRNP G) [Cleaved into: RNA-binding motif protein, X chromosome, N-terminally processed] |
Synonyms | RBMXP1 HNRPG |
Description | FUNCTION: RNA-binding protein that plays several role in the regulation of pre- and post-transcriptional processes. Implicated in tissue-specific regulation of gene transcription and alternative splicing of several pre-mRNAs. Binds to and stimulates transcription from the tumor suppressor TXNIP gene promoter; may thus be involved in tumor suppression. When associated with SAFB, binds to and stimulates transcription from the SREBF1 promoter. Associates with nascent mRNAs transcribed by RNA polymerase II. Component of the supraspliceosome complex that regulates pre-mRNA alternative splice site selection. Can either activate or suppress exon inclusion; acts additively with TRA2B to promote exon 7 inclusion of the survival motor neuron SMN2. Represses the splicing of MAPT/Tau exon 10. Binds preferentially to single-stranded 5'-CC[A/C]-rich RNA sequence motifs localized in a single-stranded conformation; probably binds RNA as a homodimer. Binds non-specifically to pre-mRNAs. Also plays a role in the cytoplasmic TNFR1 trafficking pathways; promotes both the IL-1-beta-mediated inducible proteolytic cleavage of TNFR1 ectodomains and the release of TNFR1 exosome-like vesicles to the extracellular compartment. . |
Accessions | ENST00000562646.5 ENST00000565438.1 P38159 H3BR27 ENST00000568578.5 H3BUY5 H0Y6E7 H3BNC1 ENST00000464781.5 ENST00000419968.6 ENST00000320676.11 [P38159-1] ENST00000431446.7 [P38159-3] H3BT71 ENST00000563370.1 |